Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 5/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16770005 | 0.85 | PDK1 (0.46) | PDK1IRAK4HRH3NPSR1ACKR3 | |
| SCHEMBL16767981 | 0.85 | HRH3 (0.49) | PDK1IRAK4HRH3NPSR1ALDH1A1 | |
| SCHEMBL29233712 | 0.81 | PDK1 (0.47) | PDK1IRAK4HRH3NPSR1ACKR3 | |
| SCHEMBL17020104 | 0.79 | PDK1 (0.62) | PDK1IRAK4HRH3ACKR3ALDH1A1 | |
| SCHEMBL19582110 | 0.77 | LMNA (0.54) | NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL19581875 | 0.77 | LMNA (0.54) | NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL19582108 | 0.77 | LMNA (0.54) | NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL16770006 | 0.77 | PDK1 (0.46) | PDK1IRAK4HRH3ACKR3ALDH1A1 | |
| SCHEMBL19581878 | 0.77 | LMNA (0.54) | NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL19582119 | 0.75 | ALDH1A1 (0.41) | PDK1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | PDK1 601/4885IRAK4 3644/4885HRH3 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.